首页|甲状腺肿瘤患者生化免疫检验中应用化学发光免疫测定技术的临床效果评价

甲状腺肿瘤患者生化免疫检验中应用化学发光免疫测定技术的临床效果评价

扫码查看
目的 探讨甲状腺肿瘤患者行化学发光免疫测定的临床价值.方法 目的选取扬州洪泉医院2023年1-12月收治的90例疑似甲状腺肿瘤患者为研究对象,均采用放射免疫测定(radioimmunoassay,RIA)、化学发光免疫测定(chemiluminescence immunoassay,CLIA)技术进行生化免疫检验,以手术病理结果为金标准,比较其诊断效能.结果 90例疑似甲状腺肿瘤经病理证实阳性78例,阴性12例.CLIA诊断灵敏度96.15%(75/78)、特异度91.67%(11/12)及准确率95.56%(86/90)均高于RIA的87.18%(68/78)、41.67%(5/12)、81.11%(73/90),差异有统计学意义(χ2=4.112、6.750、9.111,P均<0.05).结论 甲状腺肿瘤诊断中采取CLIA实施生化免疫检验可取得较高的灵敏度,能够为临床诊断提供重要依据.
Evaluation of the Clinical Effect of Chemiluminescence Immunoassay Technology in Biochemical Immunoassay of Thyroid Tumour Patients
Objective To investigate the diagnostic effect of chemiluminescence in biochemical immunization in pa-tients with thyroid tumors.Methods Ninety patients with suspected thyroid tumors treated in Yangzhou Hongquan Hospital from January to December 2023 were objectively selected as the study objects.Biochemical immunization was performed by radioimmunoassay(RIA)and chemiluminescence immunomeasurement(CLIA)technology.Ana-lyzed the diagnostic efficacy of both techniques using surgical pathology as the gold standard.Results Among the 90 patients with suspected thyroid tumor,78 were positive,12 were negative.The diagnostic sensitivity of CLIA 96.15% (75/78),specificity 91.67% (11/12)and accuracy 95.56% (86/90)were higher than RIA 87.18% (68/78),41.67% (5/12),81.11% (73/90),the differences were statistically significant(χ2=4.112,6.750,9.111,all P<0.05).Conclusion CLIA can achieve high sensitivity and provide an important basis for clinical diagnosis.

Thyroid tumourRadioimmunoassayChemiluminescence immunoassayBiochemical immunoassay

仝玉红、魏婷婷、胡玲

展开 >

扬州洪泉医院检验科,江苏 扬州 225200

甲状腺肿瘤 放射免疫分析法 化学发光免疫测定技术 生化免疫检验

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(15)